IBD Pharm Flashcards
infliximab
anti-TNF-alpha Ab
corticosteroids
prednisone
budesonide
hydrocortisone
5-ASA agents
delayed release
prodrugs
rectal formulations
rowasa and canasa
rectal formulation 5-ASA
delayed release 5-ASA
apriso
asacol
lialda
pantasa
prodrug 5-ASA
sulfasalazine
balsalazide
olsalazine
IBD
UC and crohns
sulfasalazine
5-ASA
prodrug
mesalamine
5-ASA
formulations
formulations of 5-ASA
so they don’t metabolize too early
can localize to specific site of inflammation
5-ASA MOA
modulate inflammatory mediators derived from COX and leukotrienes
1st line mild-to moderate UC
5-ASA
lialda and asacol
pH sensitive resin 5-ASA
pentasa
timed release 5-ASA
suppository 5-ASA
rowasa and canasa
adverse 5-ASA
sulfasalazine
nausea, GI upset, HA, arthralgia, BM suppression, malaise
corticosteroid MOA
inhibit inflammatory cytokine production as well as chemokines
travel to nucleus - modulate gene transcription
hydrocortisone
enema, foam, suppository
insomnia
corticosteroids
methotrexate
inhibits dihydrofolate reductase
anti-TNF-alpha Abs MOA
binds soluble and membrane TNF with high affinity
prevent receptor binding
cause reverse signaling and suppress cytokine release
infliximab
requires 17 weeks to be active
6 mercaptopurine
purine analog
IBS tx
laxative antidiarrheals prokinetics 5-HT3 antagonists antispasmodics antidepressants
IBS
diarrhea or constipation with abdominal pain
